Stanley Stringam, MD
Internal Medicine · Nampa, IDNPI 1902896913
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,519 of the $3,829 with a category attached, or 65.8%. 26 manufacturers reported payments, led by Novartis at 45.3% of the total. Reporting peaked in 2023 at $1,948 and has fallen 97.6% since, to $46 in 2025. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pfizer$452
- Novo Nordisk$349
- Boehringer Ingelheim$157
- Amgen$146
- Johnson & Johnson$141
- plus $849 from 20 others
Across 770 payments — averaging $598.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$155K
- Novo Nordisk AS$138K
- Eli Lilly$118K
- Sanofi US Services Inc.$27K
- Merck$15K
- Pfizer$8K
What the payments were for
- Travel & lodging$1,27733%
- Food & beverage$2,51966%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $1,735 |
| Pfizer | 35 | $452 |
| Novo Nordisk | 23 | $349 |
| Boehringer Ingelheim | 10 | $157 |
| Amgen | 9 | $146 |
| Johnson & Johnson | 10 | $141 |
| AstraZeneca | 9 | $130 |
| E.r. Squibb & Sons, L.L.C. | 9 | $123 |
| Dexcom, Inc. | 4 | $91 |
| AbbVie(2 entities) | 5 | $78 |
| GSK | 4 | $64 |
| Astellas Pharma US Inc | 4 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Abbott | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Corcept Therapeutics | 2 | $31 |
| Exact Sciences | 2 | $31 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Medtronic | 1 | $12 |
| Merck | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,485
How this compares
$3,829 in reported general payments places this provider in the 90th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $159,648 |
| TrulicityDulaglutide | 86 | $97,223 |
| OzempicSemaglutide | 55 | $71,164 |
| FarxigaDapagliflozin Propanediol | 80 | $67,597 |
| MounjaroTirzepatide | 49 | $58,944 |
| Bydureon BciseExenatide Microspheres | 25 | $26,501 |
| InvokanaCanagliflozin | 20 | $24,218 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $20,874 |
| JardianceEmpagliflozin | 20 | $20,640 |
| RybelsusSemaglutide | 18 | $20,516 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $14,919 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $14,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,378 |
| MyrbetriqMirabegron | 14 | $13,183 |
| Repatha SyringeEvolocumab | 21 | $11,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $452 | $159,648188 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $14 | $156,167135 claims |
| Novo NordiskOzempic, Rybelsus | $349 | $91,68173 claims |
| AstraZenecaFarxiga | $130 | $67,59780 claims |
| Johnson & JohnsonInvokana | $141 | $24,21820 claims |
| Boehringer IngelheimJardiance | $157 | $20,64020 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $64 | $18,13432 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $13,18314 claims |
| AbbVieArmour Thyroid | $78 | $1,15613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Nampa
- Sarah BarkerNampa$5K
- John SadajNampa$5K
- Michael DeeNampa$2K
- Ryan WilliamsNampa$492
- Sherwin D'souzaPocatello$543K
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Aditya SinghPocatello$37K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.